NV
Novavax
NVAX · NASDAQ
$9.30 -3.55% (-$0.34)
1M +16.83%
Market Cap $1.53B
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$11.85
27.4% upside
Trenutna cena
$9.3
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica NVAX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
1/9Valuation
48 /100
Fair P/S 3.70x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining Rev. growth 11.10%
Book val. growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 54.94%
Gross margin 77.85%
FCF margin 10.53%
Quality
8 /100
Poor Asset turnover 0.43x
ROIC 36.49%
ROA 25.92%
Debt
43 /100
Moderate Int. coverage -18.47x
Current ratio 2.33x
Debt/Assets N/A
Stability
3 /100
Unstable EPS volatility 145.82%
Beta 2.42x
Profitable years 1
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NVAX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Charles Jacobs
Employees
749
Headquarters
Gaithersburg
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report